Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Antiviral activity of (+)-rutamarin against Kaposi's sarcoma-associated herpesvirus by inhibition of the catalytic activity of human topoisomerase II.
[primary effusion lymphoma]
Kaposi
's
sarcoma
-associated
herpesvirus
(
KSHV
)
is
an
etiological
agent
of
several
AIDS-associated
malignancies
,
including
Kaposi
's
sarcoma
(
KS
)
,
primary
effusion
lymphoma
(
PEL
)
,
and
multicentric
Castleman
's
disease
(
MCD
)
.
Its
lytic
replication
cycle
has
been
proven
to
be
critical
for
the
pathogenesis
of
KSHV-associated
diseases
.
In
KS
lesions
,
lytic
viral
replication
,
production
of
virion
particles
,
and
reinfection
of
endothelial
cells
are
essential
to
sustain
the
population
of
infected
cells
that
otherwise
would
be
quickly
lost
as
spindle
cells
divide
.
Thus
,
antivirals
that
block
KSHV
replication
could
be
a
strategy
in
the
treatment
of
KSHV-associated
diseases
.
However
,
there
is
no
effective
anti-
KSHV
drug
currently
available
.
Our
previous
work
showed
that
human
topoisomerase
II
(
Topo
II
)
is
indispensable
for
KSHV
lytic
replication
and
is
suggested
to
be
an
effective
target
for
antiviral
drugs
.
Here
,
we
report
the
discovery
and
characterization
of
a
novel
catalytic
inhibitor
of
human
Topo
II
α
,
namely
,
(
+
)
-
rutamarin
.
The
binding
mode
of
(
+
)
-
rutamarin
to
the
ATPase
domain
of
human
Topo
II
α
was
established
by
docking
and
validated
by
molecular
dynamics
(
MD
)
simulations
.
More
importantly
,
(
+
)
-
rutamarin
efficiently
inhibits
KSHV
lytic
DNA
replication
in
BCBL-
1
cells
with
a
half
-maximal
inhibitory
concentration
(
IC
50
)
of
1
.
12
μM
and
blocks
virion
production
with
a
half
-maximal
antiviral
effective
concentration
(
EC
50
)
of
1
.
62
μM
.
It
possesses
low
cytotoxicity
,
as
indicated
by
the
selectivity
index
(
SI
)
of
84
.
14
.
This
study
demonstrated
great
potential
for
(
+
)
-
rutamarin
to
become
an
effective
drug
for
treatment
of
human
diseases
associated
with
KSHV
infection
.
Diseases
Validation
Diseases presenting
"low cytotoxicity"
symptom
dystrophic epidermolysis bullosa
esophageal squamous cell carcinoma
primary effusion lymphoma
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom